How to Get Vyleesi in Oregon

What Is Vyleesi and Who Is It For?

Bremelanotide, sold under the brand name Vyleesi, is the first and only on-demand injectable treatment FDA-approved for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. The FDA granted approval in June 2019 based on two Phase 3 RECONNECT trials enrolling over 1,200 women [1]. It works differently from flibanserin (Addyi), which requires daily oral dosing. Vyleesi is a melanocortin-4 receptor agonist administered as a 1.75 mg subcutaneous injection approximately 45 minutes before anticipated sexual activity [2].

In the RECONNECT trial (N=1,247), bremelanotide produced a statistically significant increase of 0.35 in the co-primary endpoint of desire score on the Female Sexual Function Index (FSFI-d) compared to placebo, and a corresponding decrease of -0.37 in the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) Item 13 score measuring distress related to low desire [1]. Nearly 50% of bremelanotide-treated patients reported meaningful improvement in desire, compared to roughly 36% with placebo.

Vyleesi is not indicated for men, postmenopausal women, or for enhancement of sexual performance. The FDA label explicitly limits its use to women with acquired, generalized HSDD who have not entered menopause [2].

Oregon Telehealth Rules for Vyleesi Prescribing

Oregon law allows licensed prescribers to conduct initial consultations and prescribe medications, including Vyleesi, entirely via telehealth. No in-person visit is required for a bremelanotide prescription. This makes access straightforward for patients in rural areas, from Bend to Pendleton, where specialists may be limited.

Oregon's telehealth parity laws, reinforced during the pandemic and made permanent by HB 2508 (2021), require private insurers to cover telehealth services at the same rate as in-person encounters. The Oregon Medical Board and Oregon State Board of Nursing both recognize telehealth encounters as valid for establishing a prescriber-patient relationship, provided the prescriber holds an active Oregon license [3].

A typical telehealth visit for Vyleesi takes 20 to 30 minutes. Your provider will evaluate your medical history, screen for HSDD using validated tools like the Decreased Sexual Desire Screener (DSDS), rule out other causes of low desire (depression, medication side effects, relationship factors, hormonal deficiencies), and discuss whether bremelanotide or another therapy is appropriate [4].

Prescribers may order baseline labs before writing the prescription. That happens through a local Oregon lab draw, even if your consultation is virtual.

Which Providers Can Prescribe Vyleesi in Oregon?

Oregon grants prescriptive authority to physicians (MDs, DOs), nurse practitioners (NPs), and physician assistants (PAs). All three provider types can legally prescribe Vyleesi in the state.

NPs in Oregon hold full practice authority under ORS 678.375, meaning they can diagnose, treat, and prescribe independently without a supervising physician. PAs practice under a collaborative agreement but retain independent prescribing rights for non-controlled substances. Bremelanotide is not a controlled substance, so no DEA scheduling barriers apply [2].

The right provider for you depends on your clinical situation. If you have complex comorbidities (cardiovascular disease, uncontrolled hypertension, or hepatic impairment), a physician with experience in sexual medicine may be preferable. For straightforward HSDD presentations, an NP or PA with training in women's health can manage the prescription effectively.

When evaluating a new Vyleesi candidate, the Endocrine Society's 2019 guideline on female sexual dysfunction recommends clinicians assess for modifiable contributors to low desire before pharmacotherapy, including medication-induced dysfunction (SSRIs, hormonal contraceptives), thyroid disorders, and hyperprolactinemia [5].

What Labs Are Needed Before Starting Vyleesi?

There is no FDA-mandated lab panel specifically for bremelanotide. The FDA label lists hypersensitivity, uncontrolled hypertension, and cardiovascular disease as primary contraindications [2]. Based on these, most prescribers in Oregon will order a focused set of labs to rule out other causes of low libido and confirm safety.

A standard pre-Vyleesi workup typically includes:

• Blood pressure (in-office or validated home readings over 3 days)
• TSH and free T4 to rule out hypothyroidism, which independently suppresses desire
• Prolactin to screen for hyperprolactinemia
• Total and free testosterone (yes, in women; low levels contribute to HSDD)
• Estradiol to assess hormonal status and confirm premenopausal state
• Comprehensive metabolic panel to screen for hepatic or renal impairment
• CBC as a general health screen

The Endocrine Society specifically recommends measuring testosterone in women presenting with low desire, noting that testosterone levels below the lower quartile of the normal range may warrant consideration of testosterone therapy before or alongside other interventions [5].

Lab results are usually back within 48 to 72 hours from Oregon commercial labs (Quest, LabCorp, or OHSU-affiliated draw sites). Your prescriber will review them, often asynchronously through the telehealth platform, before finalizing the prescription.

Oregon Medicaid Coverage and Prior Authorization

Oregon Medicaid (Oregon Health Plan, or OHP) covers Vyleesi with prior authorization (PA). This means your prescriber must submit documentation to the Oregon Health Authority demonstrating medical necessity before the pharmacy can fill the prescription.

PA requirements for Vyleesi under OHP generally include:

1. Confirmed HSDD diagnosis using DSM-5 criteria or a validated screener like the DSDS
2. Documentation that the condition is acquired and generalized (not situational or lifelong)
3. Premenopausal status confirmed by menstrual history or lab values
4. Exclusion of other causes of low desire (medication review, hormone panel, mood screening)
5. Trial and failure or contraindication to flibanserin (some PA forms require this step-therapy documentation)

PA turnaround through OHP is typically 3 to 5 business days. If denied, Oregon law requires the plan to provide a written explanation and instructions for appeal. Expedited reviews are available if clinical urgency is documented [6].

For commercial insurance plans in Oregon (Regence, Providence Health Plan, Moda, PacificSource), coverage varies. Many commercial plans classify Vyleesi as a specialty medication and require PA. A 2021 analysis in the Journal of Managed Care & Specialty Pharmacy found that formulary access for bremelanotide improved year over year after approval, with PA being the most common utilization management tool [7].

Out-of-pocket cost for brand-name Vyleesi without insurance runs approximately $850 to $950 for a carton of 4 single-use autoinjectors. Palatin Technologies offers a patient savings program that may reduce copays for commercially insured patients.

503A Compounding Pharmacies in Oregon

Oregon licenses 503A compounding pharmacies under the Oregon Board of Pharmacy, and these facilities can legally compound bremelanotide for patients with valid prescriptions. Compounded bremelanotide is sometimes available at a lower per-dose cost than brand Vyleesi, though insurance coverage for compounded versions is uncommon.

A 503A pharmacy compounds medications on a patient-specific basis in response to an individual prescription. This is distinct from 503B outsourcing facilities, which produce larger batches for office use. Oregon has several 503A pharmacies in Portland, Eugene, Salem, and Medford that offer compounding services, and many ship statewide.

If your prescriber writes for compounded bremelanotide, confirm that the pharmacy uses USP 797-compliant sterile compounding practices for injectable preparations. The FDA's guidance on compounding distinguishes between 503A and 503B facilities, and only pharmacies meeting state board standards should prepare sterile injectables [8].

Compounded bremelanotide is typically dispensed as a multi-dose vial with insulin syringes, rather than the brand-name autoinjector format. Your pharmacist should provide injection training or a demonstration video.

Step-by-Step: Getting Vyleesi in Oregon

The process from decision to first dose follows a predictable path. Here is what to expect.

Days 1 to 2: Schedule and complete your consultation. Book with a telehealth provider or an in-person clinician (gynecologist, sexual medicine specialist, or primary care provider). Be prepared to discuss the duration and nature of your low desire, current medications, relationship context, and mood.

Days 2 to 3: Lab draw. Your prescriber orders labs. Go to a local draw site. Results return in 48 to 72 hours.

Days 4 to 5: Lab review and prescription. Your prescriber reviews labs, confirms you meet criteria, and writes the prescription. If PA is required, the office submits documentation on the same day.

Days 5 to 10: Prior authorization (if needed). OHP takes 3 to 5 business days. Commercial plans vary. Some approve within 24 hours electronically.

Days 7 to 14: Pharmacy fills and ships. Specialty pharmacies (for brand Vyleesi) or compounding pharmacies typically dispense within 2 to 5 business days. Cold-chain shipping is not required for bremelanotide at standard storage conditions (68 to 77°F).

Day of first dose: Self-injection. Administer 1.75 mg subcutaneously in the abdomen at least 45 minutes before anticipated sexual activity. The most common side effect is nausea, occurring in approximately 40% of patients in the RECONNECT trials, though it tends to diminish with repeated use [1].

Side Effects and Safety Considerations

The FDA label for Vyleesi carries a specific warning about transient blood pressure elevation. In clinical trials, bremelanotide caused a mean systolic increase of 2 to 3 mmHg and a mean diastolic increase of 1 to 2 mmHg, peaking around 2 to 3 hours post-dose and returning to baseline within 12 hours [2].

Patients with uncontrolled hypertension (systolic consistently above 160 mmHg or diastolic above 100 mmHg) or known cardiovascular disease should not use Vyleesi. The FDA label does not set a strict blood pressure cutoff, but the prescribing information advises that bremelanotide be used with caution in patients with cardiovascular risk factors [2].

The five most commonly reported adverse reactions in the RECONNECT trials were:

| Side Effect | Bremelanotide (%) | Placebo (%) | |---|---|---| | Nausea | 40.0 | 1.3 | | Flushing | 20.3 | 1.3 | | Injection-site reactions | 13.2 | 7.8 | | Headache | 11.3 | 6.5 | | Skin hyperpigmentation | 1.0 | 0 |

Nausea severity decreased with continued use. In the 12-month open-label extension, only 6.6% of patients discontinued due to nausea [1]. Focal skin darkening occurred in about 1% of patients, primarily around the gums and face, and was generally reversible after discontinuation.

The FDA limits dosing to no more than 8 injections per month and no more than one injection per 24-hour period [2]. There is no accumulation risk at this frequency, as bremelanotide has a terminal half-life of approximately 2.7 hours.

How Vyleesi Compares to Flibanserin (Addyi)

Oregon patients often ask whether to choose Vyleesi or Addyi. The comparison matters because some insurers require step therapy through flibanserin before approving bremelanotide.

Flibanserin is a daily oral tablet (100 mg at bedtime) that works on serotonin receptors. It takes a full 4 to 8 weeks of daily use to assess efficacy. In the BEGONIA trial (N=1,087), flibanserin increased satisfying sexual events by approximately 0.5 to 1.0 per month compared to placebo [9]. It carries an FDA boxed warning against use with alcohol due to severe hypotension and syncope risk.

Bremelanotide is on-demand, used only when needed. There is no alcohol interaction and no daily commitment. The trade-off is that nausea rates are higher with bremelanotide (40% vs. approximately 11% with flibanserin), and the injection route is less convenient for some patients.

The International Society for the Study of Women's Sexual Health (ISSWSH) process-of-care algorithm positions both drugs as pharmacologic options after biopsychosocial assessment and lifestyle modification, without mandating a specific order [10]. If your insurer requires step therapy, your prescriber can document contraindications to flibanserin (e.g., hepatic impairment, alcohol use that cannot be reliably avoided, preference for on-demand dosing) to request an exception.

Transferring an Existing Vyleesi Prescription to Oregon

If you are moving to Oregon or splitting time between states, you can transfer an active Vyleesi prescription. Oregon Board of Pharmacy regulations allow inter-state prescription transfers for non-controlled medications.

Your current pharmacy calls the receiving Oregon pharmacy, verifies remaining refills, and transfers the record electronically. The receiving pharmacy must be licensed in Oregon. If your prescriber is out of state, they can continue to prescribe only if they hold an active Oregon medical license or a relevant interstate compact license. Otherwise, you will need to establish care with an Oregon-licensed provider.

For telehealth-based prescriptions, the prescriber must be licensed in the state where the patient is located at the time of the encounter. If you relocate to Oregon, your Texas-based telehealth prescriber cannot legally write new prescriptions for you unless they also hold an Oregon license.